Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Sarcoma Channel is supported with funding from Iovance Biotherapeutics (Silver).

VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

VJVirtual | NTRK gene fusions in sarcoma

Robin Jones • 20 Apr 2022

Significant response rates to NTRK inhibitors have been demonstrated in patients with sarcoma harboring NTRK gene fusions in regards to progression-free survival (PFS) and overall-survival (OS). Robin Jones, MD, The Royal Marsden Hospital, London, UK, mentions specific data whereby a median PFS of 28.3 months and an OS of 44.4 months was observed with a favorable toxicity profile, highlighting the value of identifying NTRK gene fusions in patients with sarcoma.

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.